31. The dosage form of claim 30, wherein the capsule is comprised of hydroxypropylmethyl-cellulose having a water content of 2% or less.

32. Use of the composition of claim 1 for preparation of a medicament for treating or preventing a disorder associated with digestive enzyme deficiency in a mammal in need thereof.

33. The use according to claim 32, wherein the medicament further comprises a drug that increases GI tract pH.

34. The use according to claim 32, wherein the medicament is administered in combination with a drug that increases GI tract pH.

35. The use of claim 33 or 34, wherein the drug that increases GI tract pH is selected from the group consisting of proton pump inhibitors and antacids.

36. The use of claim 32, wherein the disorder is cystic fibrosis.

37. The use of claim 32, wherein the disorder is fat malabsorption in the mammal.

38. The use of claim 32, wherein the medicament increases the coefficient of fat absorption in the mammal.

39. A method of preparing a pancrelipase composition comprising: coating particles of pancrelipase in an atmosphere having a moisture content of 3.6 g water per m^3 or less, with a coating comprising an enteric polymer and at least one inorganic material, thereby forming a plurality of delayed release particles, wherein said at least one inorganic material is talc.

40. The method of claim 39, wherein the particles are coated with a mixture of an enteric polymer dissolved in acetone and at least one inorganic material.

~~41. The method of claim 39, wherein said at least one inorganic material is talc.~~

~~42~~41. The method of claim 39, wherein the plurality of delayed release particles has a moisture content of 3% or less or water activity of 0.6 or less, and exhibits a loss of enzyme activity of no more than 15% after six months of accelerated stability testing.